Boston Life Sciences Announces R&D Management Change.

BOSTON -- Boston Life Sciences, Inc., (NASDAQ: BLSI), a development stage biotechnology company, today announced that its Chief Medical Officer, Marc Lanser, MD, will leave the Company effective June 11, 2005, to assume the role of president and CEO of FluoroPharma, Inc., a diagnostic discovery company. Dr. Lanser will join BLSI's Scientific Advisory Board (SAB) and become a scientific consultant to the Company.

"We appreciate the many contributions that Marc has made since founding BLSI in 1992," stated Peter G. Savas, the Company's Chief Executive Officer. "We are pleased Marc will join our SAB and continue to share his in-depth knowledge of our programs as well as his research and medical community relationships."

"It has been a privilege to work with Peter, the BLSI board of directors and the talented and dedicated people of BLSI," said Dr. Lanser. "As the Company continues its efforts to develop innovative approaches to address urgent medical needs for CNS disease, I am looking forward to my continuing involvement as a scientific advisor."

Boston Life Sciences, Inc. (BLSI) is a biotechnology company primarily focused in the research and clinical development of biopharmaceutical products for the diagnosis and treatment of central nervous system, or CNS, diseases.

Statements in this press release regarding management's future expectations, beliefs, goals, plans or prospects may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including those factors contained in the Company's Quarterly Report on 10-Q for the quarter ended March 31, 2005, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, the Company's actual results may differ materially from the results discussed in or implied by the forward-looking statements contained herein. Forward-looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "will" and "would" or similar words. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Our logo, trademarks, and service marks are the property of Boston Life Sciences, Inc. All other trade names, trademarks, or service marks are property of their respective owners and are not the property of Boston Life Sciences, Inc.